Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer
about
Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma markerCBX7 modulates the expression of genes critical for cancer progressionEffects of radiation therapy on tissue and serum concentrations of tumour associated trypsin inhibitor and their prognostic significance in rectal cancer patients.Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions.Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEATATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer.Tumour-associated trypsin inhibitor (TATI) in ovarian cancer.Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancersLow trypsinogen-1 expression in pediatric ulcerative colitis patients who undergo surgery.Quantification of pancreatic secretory trypsin inhibitor in colonic carcinoma and normal adjacent colonic mucosa.High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer.Role of Intrapancreatic SPINK1/Spink3 Expression in the Development of PancreatitisTumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases.Reaction of a tumour-associated trypsin inhibitor with serine proteinases associated with coagulation and tumour invasion.Role of the tumor-associated trypsin inhibitor SPINK1 in cancer development.Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance
P2860
Q31113966-E99DF135-3837-4678-9495-082A96AC6051Q35174715-512A4C4E-7EFE-49DE-95C0-B25D6EE00276Q35213711-ECBFEDA3-9FB2-46C4-974D-A9861AAC97A8Q35977970-813C5EF7-5301-4492-8666-0C12184F1551Q36028968-C4591756-FB1A-45E1-A6FE-5B2D963C7994Q36080868-D54DB402-D03D-4B2C-850A-D9F0103B2384Q36466112-54B1A499-4305-4110-89B9-46762EAAA580Q36546449-476CACD9-C1BA-410B-9CE3-C0C3218AA0B0Q36897929-1A32B821-B0B3-4686-B325-647613514A51Q37106286-1D1A9AA6-042D-4C8F-9C9E-060C3A26297EQ37228483-AD288FF6-C568-4B0B-9631-F61CC8F1E986Q38010175-A3000167-E32D-44A1-8FB6-E21C25E758A3Q41143940-8BCC03C0-4C59-4F04-A5E8-33761E4AE2AFQ41771572-3D5FBD85-3FA9-49E4-A2B8-C1D22EB3ADE6Q41852238-D6F5C70D-506A-45BC-94F8-529EDC9776A2Q58547123-BDDE8423-33E7-4D26-92DB-1EBF80DEC489
P2860
Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer
description
1982 nî lūn-bûn
@nan
1982 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1982 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1982年の論文
@ja
1982年学术文章
@wuu
1982年学术文章
@zh-cn
1982年学术文章
@zh-hans
1982年学术文章
@zh-my
1982年学术文章
@zh-sg
1982年學術文章
@yue
name
Purification and characterizat ...... a patient with ovarian cancer
@ast
Purification and characterizat ...... a patient with ovarian cancer
@en
Purification and characterizat ...... a patient with ovarian cancer
@en-gb
Purification and characterizat ...... a patient with ovarian cancer
@nl
type
label
Purification and characterizat ...... a patient with ovarian cancer
@ast
Purification and characterizat ...... a patient with ovarian cancer
@en
Purification and characterizat ...... a patient with ovarian cancer
@en-gb
Purification and characterizat ...... a patient with ovarian cancer
@nl
prefLabel
Purification and characterizat ...... a patient with ovarian cancer
@ast
Purification and characterizat ...... a patient with ovarian cancer
@en
Purification and characterizat ...... a patient with ovarian cancer
@en-gb
Purification and characterizat ...... a patient with ovarian cancer
@nl
P2093
P921
P1476
Purification and characterizat ...... a patient with ovarian cancer
@en
P2093
Huhtala ML
Kalkkinen N
Stenman UH
P304
13713-13716
P407
P577
1982-11-01T00:00:00Z